Elly Barry, MD, MMSc
Senior Medical Director, Global Clinical Lead for Pediatric Oncology and Xtandi
Elly Barry is a board-certified pediatrician and pediatric hematologist/oncologist, currently serving as the Global Clinical Lead for Pediatric Oncology at Pfizer, and responsible for developing and implementing strategy and deliverables related to pediatric development plans. While at Pfizer, she has contributed to the development of PIPs/PPSRs across a number of compounds, including bosutinib, gemtuzumab ozogamicin, inotuzumab ozogamizin, and sunitinib. She is the Head of the Pediatric Oncology Leadership Team at Pfizer, and a member of Pfizer’s Pediatric Council. She is also the Global Clinical Lead for the clinical development of enzalutamide, with a focus on prostate cancer.
Elly received her MD degree from Yale University School of Medicine in New Haven, before completing residency training in pediatrics at Tufts-New England Medical Center/Floating Hospital for Children in Boston, and fellowship training in pediatric hematology/oncology at Boston Children’s Hospital/Dana-Farber Cancer Institute in Boston. She remained on staff at DFCI as an Instructor in Pediatric Hematology/Oncology and Bone Marrow Transplantation, while obtaining a Masters in Medical Science degree from Harvard Medical School. Her previous industry roles at Genzyme and Millennium have focused on the early and late development of drugs for hematologic malignancies, breast, and renal cancers.